Evidence map›Paper›PMID 32239440›Full record

ArticleHead and neck pathology2020

Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall.

Xiang Xu, Doreen Palsgrove, Elizabeth Kurian, Shirley Yan, Bahram R Oliai, Justin A Bishop

Open access · greenAbstract read
In one paragraph

Article in Head and neck pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. RAGE Signaling in Melanoma Tumors.International journal of molecular sciences · 2020
    Review
  7. Primary cutaneous extraskeletal Ewing sarcoma of the plantar region: clinicopathological features and review of the literature.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xiang XuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Doreen PalsgroveDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Elizabeth KurianDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shirley YanDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bahram R OliaiProPath, Dallas, TX, USA.
Justin A BishopDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. justin.bishop@utsouthwestern.edu.ORCID https://orcid.org/0000-0002-9743-4360
The University of Texas Southwestern Medical Center · USPropath Services (United States) · USSouthwestern Medical Center · US

Funding

NA Jane B. and Edwin P. Jenevein M.D Endowment for Pathology at UT Southwestern Medical Center
6 · The paper itself

Abstract

Sinonasal malignant mucosal melanoma (SNM) is a rare, aggressive malignancy. The diagnosis of SNM is often quite challenging due to anatomical limitations, frequent lack of pigmentation, variable histologic appearances, and aberrant differentiation (e.g., positivity for cytokeratin, desmin, or neuroendocrine markers). S100 protein is routinely used as a standard screening marker for SNM, but it may lack optimal sensitivity. Our objective was to study the extent of immunohistochemical expression of S100 protein in SNM, and determine its diagnostic value by comparing it to a newer melanoma marker, SOX10. Twenty-three cases of sinonasal MMM were retrieved from the archival files of the Department of Pathology at UT Southwestern Medical Center. The patients included 14 men and 9 women, and ranged from 36 to 90 years (mean 64.9 years). Sections from blocks of formalin-fixed, paraffin-embedded tissue were used for immunohistochemical analysis with S100 protein and SOX10. The extent and intensity of immunostaining was recorded, and H-score was calculated. For a subset of negative or focally positive cases, S100 protein was repeated at a high-volume reference laboratory. S100 protein immunoexpression was quite variable in the SNM cases, with H-scores ranging from 0 to 300 (mean 123). While 11 of 23 cases exhibited strong and diffuse staining (H-score > 100) as expected for melanoma, 7 were weak and/or focal (H-score 1-100), and 5 were completely S100 protein-negative. For 10 cases, the negative or focal results were confirmed by reference laboratory staining. In contrast, all 23 SNM cases were diffusely and strongly positive for SOX10 (H-scores 210-300, mean 296). Our study demonstrated that S100 protein immunoexpression is extremely variable in SNM. Weak or even absent S100 protein staining is not uncommon in SNM, and should not dissuade pathologists from that diagnosis. Our data demonstrates that S100 protein is insufficiently sensitive to be used as a screening marker for SNM, but that SOX10 is consistently and robustly positive, and should therefore replace S100 protein for that purpose. Indeed, for any high-grade sinonasal tumor, pathologists must have a low threshold for utilizing additional markers to exclude the possibility of SNM.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMelanomaMiddle AgedMucous MembraneNose NeoplasmsParanasal Sinus NeoplasmsS100 ProteinsBiomarkers, TumorS100 ProteinsMalignant mucosal melanomaS100 proteinSinonasal tractSmall round blue cell tumorSOX10

Identifiers

PMID32239440
PMCPMC7669918
OpenAlexW3014116145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.